PLX-BMT as an Alternative to Bone Marrow Transplantation (BMT)

PLX-BMT (PLacental eXpanded mesenchymal stromal cells) is being developed as an allogeneic, off the shelf product that needs no matching to supplement the hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB) with the goal of improving the effectiveness of engraftments of these HSCs and shortening patient recovery time.

The differentiating factor for PLX-BMT versus traditional BMTs is that patients do not need to wait several weeks for stem cells to grow in a culture, possibly further jeopardizing their health. PLX-BMT is ready for use immediately upon arrival at the hospital where it is administered to the patient a few hours prior to the UCB injection to improve the engraftment process. Additionally, multiple PLX-BMT injections may be able to “boost” engraftment of the HSCs.

The Market for PLX BMT

PLX-BMT targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB).

Pluristem believes they have the solution for this unmet need in PLX-BMT. In preclinical studies to date, PLX-BMT has significantly improved the engraftment of UCB HSCs by up to 500% over controls.

The results pave the way towards using UCB instead of bone marrow transplants for adult patients.

PLX-BMT Expert Opinion Article  - click Here